Polio

PharmaJet Vaccine Delivery Featured at Sabin Vaccine Institute Conference

Retrieved on: 
Tuesday, March 1, 2022
Science, Other Science, Biotechnology, Pharmaceutical, Medical Supplies, Health, Medical Devices, Infectious Diseases, WHO, Social media, U.S. FDA, Vaccine, Research, Policy, Immunization, World, Sabin Vaccine Institute, CE marking, Gonzaga University, Twitter, Ecosystem, LinkedIn, Aircraft, Vaccination, Vaccine hesitancy, Certification, Solution, Polio, Use, System, COVID-19, Needle, CEO, Sabin, Caregiver, Injection, Child, Technology, Review, Partnership, Poster, World Health Organization, PQS, PharmaJet, the Sabin Vaccine Institute, the Vaccine Acceptance and Demand Initiative (VARN), PHARMAJET, THE SABIN VACCINE INSTITUTE, THE VACCINE ACCEPTANCE AND DEMAND INITIATIVE (VARN)

The poster, entitled Needle-free delivery of vaccines bridges vaccine coverage gaps in Somalia and Pakistan, is authored by J.V.

Key Points: 
  • The poster, entitled Needle-free delivery of vaccines bridges vaccine coverage gaps in Somalia and Pakistan, is authored by J.V.
  • Recent WHO-sponsored introductions of needle-free intradermal delivery of inactivated polio vaccine (ID-IPV) in Pakistan and Somalia have resulted in the immunization of over 3 million children.
  • The Sabin Vaccine Institute is a leading advocate for expanding vaccine access and uptake globally, advancing vaccine research and development, and amplifying vaccine knowledge and innovation.
  • The Sabin Vaccine Institutes Vaccine Acceptance and Demand program is actively building a multidisciplinary, global network referred to as the Vaccination Acceptance Research Network (VARN).

Worldwide Travel Vaccines Industry to 2027 - Featuring Sanofi Pasteur, Novartis and Pfizer Among Others - ResearchAndMarkets.com

Retrieved on: 
Friday, February 25, 2022
Other Travel, Pharmaceutical, Health, Travel, Risk, Travel, Awareness, Ministry, Yellow fever, COVID-19, Antibody, Disease, Molecular epidemiology, Vaccine, Infection, Ministry of Health (Saudi Arabia), Meningococcal disease, Vaccination, Incidence, Kingdom, Animal, Aquaculture, Polio, Health

Travel vaccines, also known as travel immunizations, are vaccines travelers can get before they visit certain regions across the globe which help protect them from serious diseases.

Key Points: 
  • Travel vaccines, also known as travel immunizations, are vaccines travelers can get before they visit certain regions across the globe which help protect them from serious diseases.
  • Travel vaccines work by exposing the body to a microorganism or parts of the microorganism of the disease it will protect against.
  • Other factors driving the demand for travel vaccines include increasing awareness levels, technological advancements and increasing incidence of life-threatening infectious diseases.
  • What are the major regions in the global travel vaccines market?

Direct Relief Mobilizing Emergency Aid for Ukraine

Retrieved on: 
Tuesday, March 1, 2022
Risk, Conditional sentence, Vomiting, Critical care, World War II, International Diabetes Federation, COVID-19, Accreditation, Hospital, WHO, IV, Diarrhea, Ministry, Society of Critical Care Medicine, List of health departments and ministries, Tourniquet, HIV, Medicine, Stroke, Safety, Bleeding, Sudden Attack, Norovirus, Tuberculosis, Multimedia, Oxygen, Polio, TB, Blood pressure, Critical Care Medicine (journal), HIV/AIDS, Zaporizhzhia Medical Academy of Post-Graduate Education Ministry of Health of Ukraine, Tranexamic acid, COVID, NGO, Direct Relief, Bandage, Society, Insulin, Medical device, Pharmaceutical industry, Vaccine, Health

Direct Relief is working to determine specific needs, secure requested medicines and supplies, and deliver the aid to people needing assistance, whether in Ukraine or across regional borders.

Key Points: 
  • Direct Relief is working to determine specific needs, secure requested medicines and supplies, and deliver the aid to people needing assistance, whether in Ukraine or across regional borders.
  • "Direct Relief was created out of the ashes of World War II by Europeans who fled," said Thomas Tighe, Direct Relief CEO and President.
  • Direct Relief is also in talks with medical manufacturers about securing and distributing supplies already in Ukraine, Poland and other nearby countries.
  • Since January 2021, Direct Relief has supplied Ukrainian healthcare providers with more than $27 million in medical aid.

Phase I Clinical Trial of AIM mRNA COVID-19 Vaccine (LVRNA009) Won the Praise of the Industry for High Safety and Well Tolerance

Retrieved on: 
Wednesday, January 12, 2022
Clinical trial, Vaccination, LNP, Peking Union Medical College, Vaccine, R, Disease, COVID-19, Safety, Adult, Immunization, Prevention, DEC Systems Research Center, Quality control, CAS, Public health, AIM, Chinese Academy of Medical Sciences COVID-19 vaccine, Chinese Center for Disease Control and Prevention, Efficiency, Hospital, Tsinghua University, Wuhan Institute of Virology, Fudan University, Infection, Medicine, Institute, Polio, Institute of Biomedical Science, RNA transfection, Coronavirus, III, GMT, Virology

Safety data on the phase I clinical trial was released by Director Chen Guiling of Phase I Clinical Trial Laboratory of Shulan (Hangzhou) Hospital, and the results indicated high safety and well toleration.

Key Points: 
  • Safety data on the phase I clinical trial was released by Director Chen Guiling of Phase I Clinical Trial Laboratory of Shulan (Hangzhou) Hospital, and the results indicated high safety and well toleration.
  • Compared to the phase I clinical trial results of similar products, it demonstrated excellent safety and immunogenicity.
  • At present, the phase I clinical trials of all 3 China's mRNA vaccines are carried out at the Phase I Clinical Trial Laboratory of Shulan (Hangzhou) Hospital, among which the first mRNA vaccine is already under phase III clinical trial overseas.
  • At the meeting, top-notch experts acclaimed the phase I results of the mRNA COVID-19 vaccine (LVRNA009) of AIM Vaccine.

Global Reverse Osmosis Systems Market (2021 to 2026) - Featuring Alfa Laval, Applied Membranes and Dupont Among Others - ResearchAndMarkets.com

Retrieved on: 
Monday, January 10, 2022
Utilities, Energy, City, World, Fever Dream, United Nations, Drinking water, Cholera, Death, Growth, Dysentery, World Bank, Government, Degenerative disease, Infection, WHO, Water, Urban, MIT, Diarrhea, First Nations in Ontario, World Health Organization, RO, Polio, Prevalence, Groundwater, Feces, Renewable energy, Bottled water, WPTO

Moreover, the rise in urban population and disposable income is also expected to fuel the market growth.

Key Points: 
  • Moreover, the rise in urban population and disposable income is also expected to fuel the market growth.
  • The rising investment, worldwide, to develop novel and advanced water treatment infrastructure is also expected to fuel the market growth.
  • Global estimates have been ranging from US$6.7 trillion, by the year 2030, to around US$22.6 trillion by the year 2050.
  • Countries, such as India and China, are expected to register significant market growth in the coming years.

PharmaJet partner Zydus Cadila Announces COVID-19 Vaccine Expansion Plan to Multiple Countries With Korean Firm

Retrieved on: 
Tuesday, January 4, 2022
Medical Devices, Infectious Diseases, Health, Pharmaceutical, Medical Supplies, Policy, Organic acid, COVID-19, Vaccine, U.S. FDA, Review, Therapy, Cadila Healthcare, Patient, DNA, Cancer, CE marking, US FDA, US, COVID, Degenerative disease, CEO, R & D, LinkedIn, Immunization, Inflammation, Partnership, Polio, System, Use, Certification, Technology, WHO, EUA, Injection, PQS, COVID 19, Pharmaceutical industry, PharmaJet, Enzychem, Zydus, PHARMAJET, ENZYCHEM, ZYDUS

PharmaJet , the maker of innovative, needle-free injection technology, today announced that its partner Zydus Cadila , is partnering with Enzychem Lifesciences to manufacture their COVID-19 plasmid DNA vaccine (ZyCoV-D) in Korea.

Key Points: 
  • PharmaJet , the maker of innovative, needle-free injection technology, today announced that its partner Zydus Cadila , is partnering with Enzychem Lifesciences to manufacture their COVID-19 plasmid DNA vaccine (ZyCoV-D) in Korea.
  • The vaccine will be manufactured in Korea and exported to several lower-middle income countries in Latin America and Asian New Southern Policy member countries.
  • Under the terms of this agreement, Zydus will transfer its manufacturing technology and provide technical assistance to Enzychem Lifesciences.
  • The vaccine is administered intradermally using the PharmaJet needle-free system, which can be deployed more readily, especially in resource-poor populations where these are urgently needed.

GLIDE: Yemeni Doctor Wins Global Disease Elimination Award to Help Keep the Country Free of Lymphatic Filariasis

Retrieved on: 
Monday, December 13, 2021
Philanthropy, Health, Infectious Diseases, Foundation, Pharmaceutical, Biotechnology, Award, EXPO, Neglected tropical diseases, Lymphatic filariasis, Health, Poverty, World, Onchocerciasis, Polio, Universal health care, World Health Organization, Achievement, The Global Institute for Tomorrow, Bill, Health status of White Americans, Leprosy, Maltese Falcon Society, The Bill, Partnership, Tameem Al-Kubati, LF, Pharmaceutical industry, Medical device, Management, Malaria, GLIDE, the Falcon Awards for Disease Elimination, GLIDE, THE FALCON AWARDS FOR DISEASE ELIMINATION

Dr Abdul Samid Al-Kubati, a doctor who is leading Yemens efforts to keep the country rid of lymphatic filariasis (LF) has won a Falcon Award for Disease Elimination.

Key Points: 
  • Dr Abdul Samid Al-Kubati, a doctor who is leading Yemens efforts to keep the country rid of lymphatic filariasis (LF) has won a Falcon Award for Disease Elimination.
  • The five winners were announced yesterday by the Global Institute for Disease Elimination (GLIDE) during a Universal Health Coverage Day event at EXPO 2020 Dubai.
  • Dr Al-Kubati beat 220 applicants across 44 countries to become the first Yemeni winner of the Falcon Awards.
  • The Awards invited submissions from organisations in disease-endemic countries whose proposals address cross-border, cross-disease, cross-programme, or cross-sector approaches to disease elimination.

GLIDE: Vaccination Incentives and Next Generation Sequencing – Two Pakistani Doctors Employ Innovative Techniques to Eradicate Polio

Retrieved on: 
Monday, December 13, 2021
Science, Other Science, Biotechnology, Research, Pharmaceutical, Health, Medical Devices, Infectious Diseases, Method, Award, NIH, Government, Vaccination, EXPO, Neglected tropical diseases, Lymphatic filariasis, Child, Poverty, Last mile, COVID-19, Epidemiology, Polio, National Institute, Universal health care, Foundation for the National Institutes of Health, Disease, Poliovirus, Bill, The Global Institute for Tomorrow, Infection, Onchocerciasis, Aga Khan University, Maltese Falcon Society, The Bill, Public health, Division, Partnership, Assistant, Technology, Certification, Pediatric nursing, Medical device, Vaccine, Pharmaceutical industry, Management, Malaria, Woman, GLIDE, the Falcon Awards for Disease Elimination, GLIDE, THE FALCON AWARDS FOR DISEASE ELIMINATION

Pending further successes, there are plans to scale-up Dr Das approach in all 40 high-risk areas in Pakistan.

Key Points: 
  • Pending further successes, there are plans to scale-up Dr Das approach in all 40 high-risk areas in Pakistan.
  • It is possible his methods could also be used to control other infectious diseases in the region, including COVID-19.
  • With GLIDEs support, my project will focus on improving polio vaccination coverage in these high-risk areas which will hopefully contribute to eradicating this disease from the world.
  • Dr Das and Dr Salman beat 220 applicants across 44 countries to become the first Pakistani winners of the Falcon Awards.

GLIDE: End of Malaria and Lymphatic Filariasis in Sight for Philippines, Says Award-winning Filipino Doctor

Retrieved on: 
Monday, December 13, 2021
Science, Other Science, Biotechnology, Research, Pharmaceutical, Health, Medical Devices, Infectious Diseases, Research Institute for Tropical Medicine, Award, EXPO, Neglected tropical diseases, Lymphatic filariasis, Tropical medicine, Android, Poverty, Medical specialty, Polio, Universal health care, Patient, Department, The Global Institute for Tomorrow, Prevalence, Bill, Onchocerciasis, Department of Health (Philippines), Maltese Falcon Society, The Bill, Partnership, LF, Pharmaceutical industry, Medicine, Management, Malaria, GLIDE, the Falcon Awards for Disease Elimination, GLIDE, THE FALCON AWARDS FOR DISEASE ELIMINATION

Great achievements have been made in the Philippines to tackle malaria and LF to date.

Key Points: 
  • Great achievements have been made in the Philippines to tackle malaria and LF to date.
  • However, elimination of these diseases remains problematic, and over the last five years, the country has struggled to reduce their prevalence.
  • Dr Espino beat 220 applicants across 44 countries to become the first Filipino winner of the Falcon Awards.
  • Great achievements have been made towards the 2030 goal of the elimination of malaria and lymphatic filariasis.

The Global Institute for Disease Elimination awards USD1 million to ground-breaking health projects in endemic countries

Retrieved on: 
Sunday, December 12, 2021
Infectious Diseases, Pharmaceutical, Health, Other Health, Research Institute for Tropical Medicine, Closed-end fund, Award, Government, EXPO, Neglected tropical diseases, Lymphatic filariasis, Tropical medicine, Android, Health, Poverty, World, Medical research, Epidemiology, Medical specialty, Polio, Universal Health Coverage Day, Universal health care, Patient, World Health Organization, Disease, Poliovirus, The Global Institute for Tomorrow, Department, Noguchi Memorial Institute for Medical Research, Bill, Health status of White Americans, Onchocerciasis, Aga Khan University, Florida Department of Health, The Bill, Public health, Division, Assistant, Technology, Pediatric nursing, Pharmaceutical industry, Vaccine, Management, Malaria, Woman, GLIDE, the Falcon Awards for Disease Elimination, GLIDE, THE FALCON AWARDS FOR DISEASE ELIMINATION

The Global Institute for Disease Elimination (GLIDE) has announced the winners of its inaugural Falcon Awards for Disease Elimination.

Key Points: 
  • The Global Institute for Disease Elimination (GLIDE) has announced the winners of its inaugural Falcon Awards for Disease Elimination.
  • The Falcon Awards will support community-based initiatives by empowering local actors with the tools and financial backing to rid the world of these preventable diseases.
  • For more information on The Falcon Awards for Disease Elimination and the winners, please visit: https://glideae.org/awards
    For photos of the winners, please click here .
  • The Awards invited submissions from organisations in disease-endemic countries whose proposals address cross-border, cross-disease, cross-programme, or cross-sector approaches to disease elimination.